drugset / Trial / NCT06849609
A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to evaluate safety and efficacy of intrathecal delivery of VGN-R13 as a treatment of Amyotrophic Lateral Sclerosis (ALS).
Timeline
- Start
- 2025-01-16
- Primary completion
- 2026-05
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VGN-R13 | Gene therapy (AAV / viral vector) | — | Intrathecal |